MMV055 Dose 2

Phase 1Small molecule

Medicines for Malaria Venture

MMV055 Dose 2 is one of 8 small molecule programs targeting Single Ascending Dose. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Single Ascending DoseRecruiting

Single Ascending DosePhase 1

Recruiting

Competition

Competitive Landscape

16 competitors in Single Ascending Dose

#DrugCompanyPhaseTrials

WVE-006

WWave Life Sciences Ltd.

Phase 2

1 2

SYH2085

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1

1 3

JMT202

SShanghai JMT-Bio Inc.

Phase 1

1 4

HRS-4029

BBeijing Suncadia Pharmaceuticals Co., Ltd

Phase 1

1 5

Gensci142

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1

1 6

DT-216P2

DDesign Therapeutics, Inc.

Phase 1

1 7

MMV055 Dose 2

Medicines for Malaria Venture

Phase 1

1 8

NM-101

NNeuramedy Co. Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Single Ascending Dose

NCT07011511

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants

Recruiting· Medicines for Malaria Venture logo

Medicines for Malaria Venture·Phase 1·NCT07011511·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MMV055 Dose 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MMV055 Dose 2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MMV055 Dose 2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medicines for Malaria Venture company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Medicines for Malaria Venture

MMV055 Dose 2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Single Ascending Dose1 trial

References

Drug Info

Quick Facts

Related News